Reliable Cancer Therapies: Noticias

RCT supports the ‘Fluvabrex’ and ‘Ketorolac’ trials

RCT Editor — Mon, 06 May 2013 09:44:19 +0000

Fuente:

RCT

Reliable Cancer Therapies has decided to financially support the research of two promising cancer treatments, Fluvabrex and Ketorolac. What is particularly interesting about these studies, is the fact that both Fluvabrex and Ketorolac are already approved and are used in hospitals for other indications than cancer.

Fluvabrex will be evaluated for its use in treating children with a rare brain tumor called optic-pathway gliomas. The ‘Ketorolac in Breast Cancer trial’ will look at possible anti-cancer effects of the drug ketorolac in breast cancer. Despite persuasive arguments motivating the evaluation of the possible anti-tumor effect of these drugs, these projects experienced great difficulties in finding financial support. Two important explanations for these difficulties are not at all scientifically based. It is mainly due to a lack of interest for ‘old-fashioned’ drugs and the absence of potential return on investment that these trials could not find any financial support. Because these projects have clearly demonstrated and motivated their potential, RCT has chosen to take on the financial support of these trials.

Fluvabrex is a combination of celecoxib (Celebrex®), an anti-inflammatory drug, and fluvastatin, which is normally used in adults to treat high cholesterol. These drugs are now being repurposed as potential treatment in children with refractory optic-pathway gliomas. A clinical trial will start this Spring 2013 to assess the safety of this new drug combination. Results are expected in the 2nd half of 2016.

Ketorolac is a non-steroidal anti-inflammatory drug (NSAID), sometimes used by anesthesiologists to prevent postoperative pain. It has been observed and suggested that ketorolac injection can be repurposed as an anti-cancer drug affecting the risk of recurrence of breast cancer patients. A trial to study this hypothesis has started in February of this year and will recruit patients over 2 years.

RCT is always looking for new studies evaluating existing and approved drugs as possible new cancer treatments. To submit projects or to request more information, please use the ‘call for projects’ button on our website.

New update available of Guide for Patients with Breast Cancer

RCT Editor — Fri, 29 Mar 2013 11:07:39 +0000

Fuente:

RCT

Last year was a productive year, as RCT managed to develop no less than 8 new Guides for Patients and updated another 2 in collaboration with the European Society of Medical Oncology (ESMO). These updates are of vital importance, as they reflect the progress in the ever evolving treatment options in oncology. This year will be no different. The first update of the Breast Cancer Guide for Patients is already online on the RCT website. This update mainly encompasses an elaboration of the ‘treatment options’ section, as there have been new treatments made available for breast cancer. Next to this, some other changes have been made with respect to the possible side effects. Next to the topics of treatments and side effects, the Guides for Patients also discuss the following issues:

The frequency of the cancer type
The possible causes
The diagnostic methods
All details to understand what defines an optimal treatment
What to do after therapy has been terminated

Reliable Cancer Therapies seeks to provide reliable information on every cancer type, and with these Guides for Patients RCT wants to elaborate on the information that is already made available on their website. Yet the development of these guides takes time as they are a result of many critical reviews of professionals at both RCT and ESMO and of patients’ representatives of the ESMO’s Cancer patient Working Group. RCT is currently finalizing two new guides who will become available very soon. The topics of those guides are ovarian and colorectal cancer. As both are rather common cancer types, RCT believes that this information is truly necessary and will be of great help for patients in order to better understand their disease and be involved in all decisions.

Fresh seasonal fruit and vegetables represent the basis of many diets and a healthy lifestyle

Ann-Christine Moenaert — Fri, 22 Mar 2013 15:27:13 +0000

Fuente:

RCT

As March was proclaimed the Month of National Nutrition 2013 in the USA (http://www.eatright.org/nnm/), we believe now is the perfect time to focus on the information on nutrition that is available on our website. Because a healthy diet is very important and can also contribute to a smoother healing process for people with cancer, RCT pays attention to nutrients and investigates scientifically both positive and negative characteristics of a variety of nutrients, supplements, and diets.

A recent article ‘Eat Healthy, Feel Happy’ again demonstrated that daily consumption of fruit and vegetables makes people happier and protects them from diseases like cancer. Because they are full of vitamins and nutrients, it is not surprising that fresh fruit and vegetables are often part of diets. RCT provides reliable information on its website on various types of diets and describes their effect in a scientifically substantiated way.

Find more info on diets by name here.
This diets page has been extended recently with reliable information on the Moerman diet, the Lifestyle and Modification Programme of Ornish, and the Gerson therapy. All three diets recommend the consumption of fresh vegetables and fruit for the body to be able to absorb enough nutrients.

For more information on the Ornish diet, click here.
For more information on the Moerman therapy, click here.
For more information on the Gerson therapy, click here.

RCT celebrates Rare Disease Day

Ann-Christine Moenaert — Thu, 28 Feb 2013 11:22:29 +0000

Fuente:

RCT

Thursday, February 28, 2013 is Rare Disease Day (www.rarediseaseday.org) tending to people not given adequate attention and often not enough research for their disease. Reliable Cancer Therapies celebrates Rare Disease Day today and every day with their work to help people with all types of cancer, including those more rare in the cancer world.

“Cancer is very complex and impacts many locations in the body. Reliable Cancer Therapies recently made the decision to incorporate information about rare cancer types. We want to help as many cancer patients and discuss as many cancer types as possible, and not overlook rare cancers,” said Lydie Meheus, PhD, Executive Director of RCT.

Reliable Cancer Therapies, a non-profit in Europe to help cancer patients through their educational website with research-based information and selectively funding the development of promising cancer therapies, passionately strives to feature common cancer types such as breast cancer plus rare cancer types. Those rare cancer types addressed by RCT include malignant peritoneal mesothelioma, adrenal cortical cancer, eye cancer, kaposi’s sarcoma, merkel cell tumor, gestational trophoblastic disease, nasal cavity and paranasal sinus cancer, neuroblastoma, penile cancer, retinoblastoma, pituitary tumors, salivary gland cancer, small intestine cancer, thymus cancer, vaginal cancer, and vulvar cancer.

Cancer information from RCT has been developed in part from the National Cancer Institute and translated into Dutch and French.

Learn more about RCT, including rare cancer types addressed by them, at www.reliablecancertherapies.com.

New Guides for Patients available on Bladder Cancer and Chronic Myeloid Leukemia (CML)

Jessica Kiermeer — Wed, 06 Feb 2013 12:14:22 +0000

Fuente:

RCT

Reliable Cancer Therapies (RCT) and the European Society of Medical Oncology (ESMO) have once again collaborated for the development of another two Guides for Patients on Bladder Cancer and Chronic Myeloid Leukemia, respectively. As is the case with the previous Guides for Patients, these documents may help patients in understanding their disease by means of providing them with patient-friendly information on cancer stages, medical procedures, possible side effects, and much more.

At this moment, bladder cancer is the 5th most common cancer in Europe, with 27 out of 100.000 men and 5 out of 100.000 women diagnosed every year. The occurrence number for Chronic Myeloid Leukemia, however, is lower as it is less common in Europe, with yearly only one or two people (men or women) diagnosed in every 100.000 people.

Reliable Cancer Therapies seeks to provide patients with the most up-to-date information available, and therefore yearly revises the guides as well as all other info on its website. The Guide on Chronic Myeloid Leukemia has been recently updated in all languages, containing the most recent therapeutic options and guidelines.

To find out more about these cancer types, visit the RCT website: Bladder cancer ; Chronic Myeloid Leukemia (CML). Both pages also provide direct links to clinical trials that are available for these cancer types in European countries.

The Alexine Clarysse Fund will fund RCT's research for cancer in children and teenagers

Jessica Kiermeer — Tue, 18 Dec 2012 15:26:11 +0000

Fuente:

RCT

The Alexine Clarysse Fund will fund RCT's research that will investigate Mindfullness with two supplements for children and teenagers.

The group of teenagers (14-19 years) that has completed its cancer treatment will take part in mindfulness therapy sessions during 8 weeks, this in combination with two supplements on the basis of curcumin and green tea.

The purpose of this study is to examine whether these two interventions can improve the quality of life of young people.

For more information on Alexine Clarysse Fund, please visit this site.[Dutch only]

Two new Guides for Patients available: NSCLC and Cervical Cancer

Jessica Kiermeer — Thu, 13 Dec 2012 08:28:28 +0000

Fuente:

RCT

Reliable Cancer Therapies is glad to announce that reliable patient-oriented information is now available on Non-Small Cell Lung Cancer (NSCLC) and Cervical Cancer. Indeed, another successful collaboration with the European Society of Medical Oncology (ESMO) resulted in two new Guides for Patients on two major cancer types that to this day have a high incidence rate and are amongst the main causes of cancer-related deaths worldwide.

Despite screenings and vaccinations protecting against the Human Papilloma Virus (HPV), cervical cancer remains the third most frequent cancer in women worldwide, mainly because of problem of accessing screening programs and vaccines in developing countries. As for non-small cell lung cancer, it represents 80 to 85% of all lung cancers and is the most frequent cause of cancer-related deaths in both sexes worldwide.

Luckily, there are things you can do to early detect or even prevent these cancers. Cervical cancer, for instance, can be easily detected and treated at an early stage after a pap smear test, carried out by a gynecologist. As for lung cancer, approximately 90% of lung cancers among men and 80% among women are related to smoking. No need telling you quitting smoking is a very effective preventive action. So two ideas for good intentions for the New Year: quit smoking, and women: go see your gynecologist on a regular basis!

Please, read our guide by clicking here: NSCLC and Cervical cancer.

These guides will tell you more on the diagnosis procedure, causes, treatment options, and possible side effects of treatments.

New update of Breast Cancer Guide for Patients available!

Jessica Kiermeer — Mon, 01 Oct 2012 06:56:09 +0000

Fuente:

RCT

As breast cancer is still the most common of all cancers in women, Reliable Cancer Therapies (RCT) believes that keeping cancer patients and their close relatives well-informed about breast cancer, its stages and, what is most important, the possible treatment options per stage, is still a number one priority. October being the BREAST CANCER AWARENESS MONTH therefore is the perfect time for RCT to update its Guide for Patients with Breast Cancer, which it has developed in cooperation with the European Society of Medical Oncology (ESMO). The main reason for developing this new version, is to extend the information on the different types and stages of breast cancer. Indeed, all these different types need other, particular treatment procedures. This extensive information is, of course, crucial for cancer patients undergoing these treatments in order to fully understand the content of their treatment, the reason why they need it, and the possible results or side effects.

The update is now freely available from the RCT website (www.reliablecancertherapies.com), as is all other research-based information on therapies and cancer types.

A new Guide for Patients on Esophageal Cancer

Ann-Christine Moenaert — Fri, 22 Jun 2012 09:06:46 +0000

Fuente:

RCT

It’s that time of the year again: summer, an ideal time to throw garden parties and go outside for a drink. Reliable Cancer Therapies therefore thinks it is an appropriate moment to remind you about the dangers of excessive alcohol intake, as this remains a major risk factor for the development of various cancer types. This is also the case for esophageal cancer. The higher the intake of alcohol, the higher the chance of getting an esophageal cancer. Combine this with excessive smoking (one package a day), and you get a very dangerous carcinogenic cocktail.

Because esophageal cancer makes the top 10 of most common cancers worldwide (8th place) with a yearly approximately 500 000 new cases, RCT has created a Guide for Patients with Esophageal Cancer for patients and their relatives. This guide provides all kinds of information on, amongst other things, treatment modalities, risk factors, and follow-up. Next to this guide, RCT also provides information on clinical trials for this cancer type, which you can retrieve here.

31-MAY-2012: World No Tobacco Day

Ann-Christine Moenaert — Mon, 28 May 2012 23:19:09 +0000

Fuente:

RCT

The annual World No Tobacco Day, which will take place on Thursday 31th of May is an excellent moment to think about the impact of smoking. This is indeed one of the most important risk factors of lung cancer, a disease which in Belgium only is already diagnosed in an average of 5400 men and 1800 women each year. For lung cancer patients and their relatives the access to reliable information is of vital importance.

Reliable Cancer Therapies (RCT) has already collected some reliable information on this cancer type, both on Small-cell lung cancer (http://www.reliablecancertherapies.com/cancers/lung-cancer-small-cell-lung-cancer) and on Non-small-cell lung cancer (http://www.reliablecancertherapies.com/cancers/lung-cancer-non-small-cell-lung-cancer). RCT is also currently developing a Guide for Patients with Non-small-cell Lung Cancer, which will be published on our website by the end of August of this year.
Next to this cancer specific information, we also provide info on clinical trials that are ongoing or planned per cancer type. For lung cancer, you can find this information here.

Reliable Cancer Therapies needs Angels

Jessica Kiermeer — Mon, 16 Apr 2012 10:26:17 +0000

Fuente:

RCT

Retrieving reliable information on cancer types, stages, and possible treatments is without a doubt crucial for cancer patients when it comes to making the right treatment choices and dealing with the disease. However, one should not neglect the fact that patients and their relatives also need a lot of support, someone who listens to them, and practical advice which enables them to deal with the daily inconveniences of cancer, and to relieve them. Therefore, RCT would like to start a project with the cooperation of the non-profit organization Imerman Angels (www.imermanangels.org), which connects cancer patients, cancer survivors, and other volunteers in order to offer this necessary support.

About Imerman Angels:

Imerman Angels is a non-profit organization which is dedicated to helping cancer patients by means of providing personalized connections that enable one-on-one support among cancer patients and survivors of the same cancer type (called Angels). When making these one-on-one connections, they try to take into account as much as possible the resemblances between the cancer patient and the Angel (mostly a cancer survivor) with respect to cancer type, age, and family situation, so as to provide optimal one-on-one support. Given that the Angels have gone through (almost) the same thing, they are the most appropriate people to answer all kinds of specific and practical questions which cancer patients deal with. Through online skype and/or chat sessions both parties contact each other on a regular basis (e.g.: 2hrs/week). Contact by mail or e-mail is also possible.

The Angels project of RCT:

Given that in Belgium (or even throughout Europe) no such networks for one-on-one support are available, RCT would like to cooperate with Imerman Angels in order to also provide Belgian/European cancer patients and their relatives with this personal support tool. Therefore, RCT is looking for volunteers (cancer survivors) and cancer patients that are willing to make such one-on-one connections. You can enroll on the website of Imerman Angels as a patient or as an Angel. When all the information has been collected, the organization can provide optimal connections among the two groups and coordinate the one-on-one support. Because this project is accessible worldwide, although mostly successful in the U.S., this support is mostly given in English. However, it is also possible to receive this support in your own language provided that there are appropriate volunteers in your language or that there is an intervention of an interpreter. If necessary, RCT is also willing to train/support people who would like to present themselves as an Angel, but who are insecure about the exact approach.

For the time being, our intention is to evaluate the project and to check whether there is a need for a similar concept in Belgium/Europe. If this project shows good results, RCT will possibly develop a local project in the future. Therefore, RCT asks all participants to give feedback on this project and to share their experiences.

How to enroll?

Are you eager to be a volunteer who supports cancer patients, or do you, being a cancer patient yourself, need someone who can truly understand you, then send us an e-mail with your personal information to info@reliablecancertherapies [dot] com entitled “Imerman Angels Project”. We will provide you as soon as possible with the information that you will need to enroll as well as to give feedback.

Do not forget to mention the following information:

- Name
- Age
- Domicile
- Cancer type
- Family situation (e.g.: partner, number of children)
- Knowledge of English: Poor/little/good/perfect

On behalf of the Reliable Cancer Therapies team we thank you for your interest in the project.

The RCT website has a new therapy page

Jessica Kiermeer — Fri, 06 Apr 2012 07:20:57 +0000

Fuente:

RCT

Reliable Cancer Therapies (RCT) is pleased to announce the addition of a new page to its website: Energy-based therapies. This webpage will provide information about cancer therapies in the field of energy medicine. Energy medicine is a term generally used for holistic healing therapies that are focused on manipulating the human body’s energies to bring about balance and well-being. Energy-based therapies as defined by RCT, on the other hand, are practices that use instrument-generated energy to either kill cancer cells or stimulate the body to restore health. This more restricted concept of energy medicine encompasses all therapeutic cancer treatments based on the physical interaction of cancer cells with the energy delivered to the body. The instruments use electricity, ultrasound, magnetic and electromagnetic (EM) forces including radio waves, laser beams and rays from other parts of the EM spectrum. They may involve the use of specific, measurable wavelengths and/or frequencies to treat patients with cancer. The majority of these therapies, however, are still at clinical trial, preclinical experimental or purely experimental stage. Much remains to be learned about their mechanisms of action and efficacy. This preliminary outline of energy-based therapies should not be viewed as comprehensive or definitive. Rather, it is intended to provide you with a sense of the possibilities offered by energy-based approaches generally unknown to the broader public.

The information that you will find in this section is written by an RCT author and reviewed by experts in the field. The reviews are available in a format ‘for patients’ and a format ‘for professionals’. The latter is more extensive and contains information about the therapy’s mechanisms of action and recent clinical outcomes. For ease of reading PDFs can be downloaded from the site. RCT reviews currently available are “Hyperthermia in cancer treatment” and “Thermal ablation in cancer treatment”. At the moment we are assessing the role of Photodynamic therapy in cancer treatment and a summary will be added soon. This will be followed by two rather controversial therapies, namely Electrotherapy and Electromagnetic therapy. We would like to welcome everyone to share with us relevant information or comments particularly regarding these therapies at info@reliablecancertherapies [dot] com.

Liver Cancer: still the fifth most common cancer in men worldwide

Jessica Kiermeer — Tue, 27 Mar 2012 06:54:21 +0000

Fuente:

RCT

Given that liver cancer is the fifth most common cancer in men worldwide (523 000 cases per year, 7.9% of all cancer cases) and the seventh in women (226 000 cases per year, 6.5% of all cancer cases), we think that reliable information for patients on this cancer type is indispensable. Therefore, we are happy to announce that there is a new Guide for Patients available on our website: A Guide for Patients with Liver Cancer. This Guide has been written by Reliable Cancer Therapies (RCT) and is based on the ESMO guidelines.

As shown on the figure, the regions of high incidence (dark red) are Eastern and South-Eastern Asia, and Middle and Western Africa. Lower rates (light pink) are observed in developed regions, with the exception of Southern Europe where the incidence in men is significantly higher than in other developed regions.

In Belgium, 413 men and 192 women were diagnosed with liver cancer in 2008. The mean age at diagnosis is 66 years in males and 68 years in females. Under the age of 25 years, liver cancer is very rare.

RCT proposes this guide for free on its website to provide patients and their relatives with reliable information on liver cancer. In this guide, you can find, amongst other information, the diagnosis procedure, an enumeration of possible causes of the disease and treatment options, as well as some valuable advice to help patients and relatives cope with the diagnosis and treatment. This information is, moreover, written in an understandable and patient-friendly way. You can easily download this Guide for Patients in four languages (EN, NL, FR, ES).

New Guide for Patients with stomach cancer available

Reliable Cancer Therapies — Fri, 03 Feb 2012 13:31:10 +0000

Fuente:

RCT

On Saturday 4th of February 2012, it is World Cancer Day. Therefore, we think it is an excellent moment to inform you about the novelties on the Reliable Cancer Therapies (RCT) website. We are happy to announce that there is a new Guide for Patients available on our website: A Guide for Patients with Stomach Cancer. This Guide has been written by RCT and is based on the ESMO guidelines.

Because stomach cancer is the fourth most common cancer worldwide, with almost 1 million new cases and 740.000 deaths each year we think that reliable information for patients on this cancer type is indispensable. Stomach cancer is the second most common cause of cancer death worldwide (after lung cancer) and more than half of the cases occur in East-Asia (esp. Korea, China and Japan). Stomach cancer is less frequent in Belgium nowadays, and represents less than 5% of all cancers. It occurs mostly in male after the age of 60.

RCT provides this guide for free on her website to inform patients and their relatives as good as possible about stomach cancer and the treatment options. This information is, moreover, written in an understandable and patient-friendly way. You can easily download this Guide for Patients in four languages (EN, NL, FR, ES).

ESMO presents its new President Dr. Martine Piccart

Reliable Cancer Therapies — Fri, 13 Jan 2012 13:13:07 +0000

Fuente:

RCT

We are proud to announce that Dr. Martine Piccart, an active member of our own Scientific Advisory Board, is now appointed ESMO President 2012-2013!

Being an active member of many professional organizations, Dr. Piccart has developed a lot of expertise with respect to drug development, clinical trials and oncology in general. She is, for instance, past-president of the European Organization for the Research and Treatment of Cancer (EORTC) and recently served on the American Society of Clinical Oncology (ASCO) Board.

We are certain that Dr. Piccart’s 2 years of ESMO presidency will make a real difference in cancer care in Europe. This is illustrated in the video where she briefly explains her priorities, of which the following three have a high priority level:

Reduce the inequalities in cancer care in Europe
Prepare the next generation of medical oncologists
Increase the number of patients included in clinical trials in Europe to at least 5% of all cancer patients

For more information on Dr. Martine Piccart, click here.

The symposium on non-conventional therapies and cancer was successful!

Reliable Cancer Therapies — Tue, 10 Jan 2012 07:42:56 +0000

Fuente:

RCT

We are glad to announce that the symposium on non-conventional therapies and cancer, organised by Reliable Cancer Therapies and the Foundation Against Cancer (Belgium) on the 9th (Dutch) and 16th (French) of December 2011, was very successful!.

We like to thank everyone who participated and we hope to see you again at our future informative events.

For more information, click here (website available in Dutch and French only).

You can also take a look at the program booklet or some pictures.

New project: Adoptive T cell transfer and vaccination as treatment for stage IV melanoma in patients

Reliable Cancer Therapies — Tue, 27 Dec 2011 09:13:21 +0000

Fuente:

RCT

RCT starts financing a new project of the Leids University Medical Centre (Netherlands). These Dutch researchers investigate Adoptive T cell transfer and vaccination as treatment for stage IV melanoma in patients. The activation and expansion of tumor reactive T cells outside a patient’s body and their subsequent re-infusion (adoptive cell transfer (ACT)) is at this moment the most effective approach to induce objective anti-tumor responses in end-stage metastasized melanoma patients. In this study patients will also be vaccinated with their own tumor cells in order to increase the in vivo effectiveness of transferred T cells even more.

For more information on this project, click here.

The RCT Advisory Board has a new member!

Reliable Cancer Therapies — Tue, 13 Dec 2011 13:01:36 +0000

Fuente:

RCT

We are proud to present Mr. Jan Geissler as the newest member of our Advisory Board!

Being a leukemia survivor who participated in various clinical trials himself, Mr. Geissler founded an online patient community for leukemia patients and started devoting his professional life entirely on patient advocacy in 2008. Given that he actively participates as a patient’s representative in a variety of important steering committees and advisory boards of cancer-related organizations, clinics and universities, he is the right person to reinforce our Advisory Board and provide us with the advice, support and knowledge that will be very useful in fulfilling our mission.

For more information on Mr. Jan Geissler, click here.

RCT offers new guides for patients with general information.

Jessica Kiermeer — Wed, 07 Dec 2011 10:01:02 +0000

Fuente:

RCT

To celebrate the first anniversary of the website, Reliable Cancer Therapies (RCT) launches new guides for patients with general information in the hope of offering cancer patients, as well as their relatives, some answers to a wide range of questions and problems concerning treatment types, changes to lifestyle habits, the relationship with the oncologist, and many other concerns which cancer patients have to deal with.

Moreover, all of these guides are easy to download and print.

For more information, read the entire press release here:

RCT offers general guides for cancer patients

Verbier - Reliable Cancer Therapies (RCT) celebrates the first anniversary of its website in style. The Swiss non-for-profit organization has completed comprehensive guides for cancer patients and their relatives, which are now available on its website, www.reliablecancertherapies.com/guides/general.

“When you’re diagnosed with cancer, your world falls apart”, says Lydie Meheus, Executive Director of RCT. “Therefore, we wanted to offer these patients clear guides that can help them to better understand what they are going through and guide them along this difficult journey. Clear and reliable information is crucial in relieving anxiety and panic, which are common feelings amongst cancer patients and their relatives.”

Given that most cancer patients deal with the same issues and have the same questions, RCT now offers two new guides with general information next to the existing ones per cancer type to address these common concerns. These concerns may include the following topics: questions to ask your oncologist, the pros and cons of participating in clinical research, looking after quality of life, information retrieval, second opinions, etc. There are currently two general guides available: one for patients who are just diagnosed with cancer, and another one for patients with advanced cancer.

Other new general guides are available on the following topics:
• Non-conventional therapies
• Conventional therapies
• Integrative cancer care
• Nutrition & physical activity
• Energy-based therapies
• Supplements
• Mind-Body Medicine

“Based on our experience in dealing with patient questions, we realized that there is an unmet need for guidance in the jungle of cancer information”, explains Meheus. “Having this information available in the mother tongue is a must.”
The guides are evidence-based, written in a clear, comprehensible language, and provide definitions and explanations.

Website makeover
The guides can be downloaded from the RCT website, which has expanded considerably since its launch in November 2010. It is also certified with the HONcode label since September 2011. The Health on the Net Foundation (HON) acknowledges through this label that the health information provided on www.reliablecancertherapies.com is scientifically correct, reliable and used efficiently. By means of verifying the quality, objectivity and transparency of the medical information available on the Worldwide Web, the organization can help people distinguish between reliable and unreliable information.

“Having the ethical HONcode label on our website means a lot to us”, acknowledges Luc Verelst, founder and chairman of RCT. “People can be sure that the information has been thoroughly evaluated and has been deemed reliable and accurate. This was what we wanted to offer in the first place: reliable information on cancer types and therapies.”

About RCT
RCT investigates the information on cancer therapies for evidence, so that evidence-based treatment choices can be made. RTC helps patients to structure and absorb the complex nature of information on registered, complementary or alternative therapies.
The RCT team is independent and open-minded, supported by a high level advisory board, collaborates with international organizations (ESMO, CAM-CANCER), and consults reliable sources (NCI, MSKcc, Natural Standard, a.o.).

RCT is constantly looking for cancer therapies that – based on measurable results – seem successful, but have never been investigated thoroughly. If in the course of these investigations promising new cancer treatments are identified, the development of such therapies can be funded.
The RCT website provides research-based information for both patients and their relatives, and professionals so that it can be used to discuss treatment options.

Contact Information:

Reliable Cancer Therapies

Head office Switzerland:
1936 Verbier - Switzerland

Representative office Belgium:
Boechoutlaan 221
1853 Strombeek-Bever - Belgium

info@reliablecancertherapies [dot] com
www.reliablecancertherapies.com

The RCT website has a new QUESTIONS page

Jessica Kiermeer — Thu, 13 Oct 2011 14:02:13 +0000

Fuente:

RCT

From now on you can find a list of questions our team received from cancer patients and their relatives in the QUESTIONS tab. If you click on these questions you can immediately retrieve the answers to the questions you might have been dealing with for a long time. All answers have been carefully written by professionals of our team with the goal of being as accurate, clear and reliable as possible.

If you have a question that has not yet been included in this list, please send us an e-mail with your question to info@reliablecancertherapies [dot] com.

Recommendation against routine PSA test

Ann-Christine Moenaert — Mon, 10 Oct 2011 14:31:53 +0000

Fuente:

RCT

The medical world reacts startled to the leaked draft recommendation written by the USPSTF regarding the prostate-specific antigen (PSA) Test. The adapted version of an earlier recommendation states that the PSA Test has no remarkable benefits and should, therefore, not be recommended to men, including men younger than 75. The USPSTF argues that the PSA screening is often used inappropriately, causing men with a low-risk profile to undergo unnecessary treatments for prostate cancer and, consequently, to expose themselves to the risks associated to those treatments (such as erectile dysfunction, urinary incontinence, and bowel dysfunction).

The recommended change is based on a review of 5 randomized trials of screening and 3 trials and 23 cohort studies of treatments. Included in the review were the 2 largest trials of PSA screening, which reported conflicting results, the USPSTF notes. The European study found a reduction in mortality after 9 years of screening, but the American trial found no reduction in mortality after 10 years of screening.

Proponents of the PSA screening acknowledge the imperfection of the test (as it is not specific for prostate cancer and it cannot differentiate between aggressive and indolent forms of the disease), but stress the importance of the test for early diagnosis primarily.

A summarized paper of the recommendation, which appeared in the Annals of Internal Medicine, is available here.

Great breakthrough in cancer research

Ann-Christine Moenaert — Mon, 26 Sep 2011 09:24:36 +0000

Fuente:

RCT

Researchers have revealed a new cancer drug for patients with HER2- positive metastatic breast cancer at the European Multidisciplinary Cancer Congress 2011 in Stockholm. T-DM1, trastuzumab emtansine, is a cytotoxic agent linked to an antibody, that specifically targets HER2- positive metastatic cancer cells. Patients who have received this drug during the phase II- trials had significantly fewer side effects and had a longer time to live without their disease worsening in comparison to patients who have received standard chemotherapy treatment.

For more information, consult the ESMO (European Society for Medical Oncology) website

New therapies on the website: Autogenic therapy, Biofeedback and Progressive Muscle Relaxation

Ann-Christine Moenaert — Fri, 16 Sep 2011 20:10:22 +0000

Fuente:

RCT

The CAM-cancer summaries for Autogenic therapy, Biofeedback and Progressive Muscle Relaxation (PMR) are now available on the website.

Therapeutic claims of Autogenic therapy for cancer patients include a reduction in state anxiety, pain, depressed mood symptoms, improved sleep parameters and generic quality of life. However, the assessed studies have not been reproduced and have considerable methodological limitations.

The professional version of this information has been written by Helen Cooke and reviewed by the CAM-cancer consortium. The version for patients has been based on this review and is available here.

Proponents believe that Biofeedback is a process that enables an individual to learn how to change physiological activity. Therapeutic claims of Biofeedback for cancer patients involve an improvement in pain relief and chemotherapy-related nausea and anxiety. Yet, the evidence for the use of this therapy remains insufficient due to the considerable methodological limitations of the conducted studies.

The professional version of this information has been written by Helen Cooke and reviewed by the CAM-cancer consortium. The version for patients has been based on this review and is available here.

There is only limited evidence for the effectiveness of PMR for cancer patients suffering from pain, anxiety, depression, sleep disorders and chemotherapy-induced nausea. Due to the low number of published studies and the methodological weaknesses it is almost impossible to test the efficacy of PMR.

The professional version of this information has been written by Helen Cooke and reviewed by the CAM-cancer consortium. The version for patients has been based on this review and is available here.

The RCT website is HON-code certified

Ann-Christine Moenaert — Mon, 05 Sep 2011 12:02:36 +0000

Fuente:

RCT

RCT is proud to inform you that our website is from this day on, September 5^th 2011, HONcode certified. This means that the Health on the Net Foundation (HON), acknowledges that the health information provided on our website is scientifically correct, reliable and used efficiently. The HON Foundation, founded in 1995, is a non-profit, non-governmental organization, which wants to protect citizens from misleading information concerning health. By means of verifying the quality, objectivity and transparency of the medical information available on the Worldwide Web, the organization can help people distinguish between reliable and unreliable information. If a website has received such an ethical HONcode seal, people can be sure that the information has been thoroughly evaluated and has been deemed reliable and accurate. Apart from our website, a good example of a reliable, HONcode certified health website is the American Cancer Society website.

RCT signs partnership with Preclinical Oncology Services Ltd

Ann-Christine Moenaert — Fri, 12 Aug 2011 11:38:46 +0000

Fuente:

RCT

Precos is a leading preclinical research and development service provider based in the UK. The company has a specific focus on oncologic research, evaluating oncology therapies for major pharmaceutical and biotech companies worldwide, making it an ideal partner for the Artemisia annua project of RCT.

With its broad experience and vast reputation in the scientific field, Precos will provide a scientific evaluation of several products based on the plant Artemisia annua (or Sweet Wormwood) for its anticancer activity in mice. RCT can use this information to select the best candidate for further studies in humans.

Since RCT wants to bring reliable information on cancer therapies to both patients and professionals, extended research is necessary. With the dedicated help of Precos, they will bring RCT closer to achieving its goals.

La EMA aprueba Ipilimumab para el tratamiento del melanoma metastásico

Klara Rombauts — Fri, 15 Jul 2011 12:30:02 +0000

Fuente:

RCT

El 28 de marzo del 2011 la FDA aprobó Ipilimumab para el tratamiento del melanoma metastásico (estadio avanzado), la forma más peligrosa de cáncer de piel.
La EMA aprobó este medicamento el 14 de julio del 2011.
Ipilimumab es un medicamento que ayuda al sistema immune a matar células cancerosas. Este medicamento será estudiado en ensayos clínicos para evaluar las posibilidades de tratamiento de otros cánceres.
La información proveída por RCT referente a Ipilimumab se encuentra disponible aquí.

31 de mayo de 2011: 'Día Mundial sin Tabaco'

Ann-Christine Moenaert — Tue, 31 May 2011 07:18:31 +0000

Fuente:

RCT

Hoy, 31 de mayo, es el Día Mundial sin Tabaco, una iniciativa de la Organización Mundial de la Salud (OMS) y tradición desde 1988.
A pesar de que puede provocar accidentes cerebrovasculares (ictus), enfermedades cardiovasculares y diversos tipos de cáncer, el uso de tabaco continúa creciendo.

La epidemia de tabaco mata a más de 6 millones de personas al año. Entre sus víctimas no sólo se cuentan los fumadores activos, sino también los fumadores pasivos, que se ven forzados a aspirar el humo de los fumadores que tienen cerca.

Puesto que los niños de muchos países continúan sin protección contra el humo en los espacios públicos, como escuelas y restaurantes, la mitad de los niños de todo el mundo respira habitualmente humo de tabaco. Además, el 40 % tiene al menos un progenitor que fuma. Por ello, muchas de las muertes que provoca el tabaco se producen en niños, debido a que fueron fumadores pasivos o a que sus madres fumaron durante el embarazo.

No hace falta repetir que el tabaquismo es una de las mayores amenazas contra la salud pública.

La OMS está decidida a continuar su lucha contra el tabaquismo, ofreciendo ayuda a los que quieren dejar de fumar y protegiendo a las personas contra el tabaco.

Puede encontrar más información sobre el Día Mundial sin Tabaco aquí.

Puede encontrar ayuda para dejar de fumar aquí.

RCT lanzará “Guías para Pacientes” en su sitio web

Ann-Christine Moenaert — Mon, 16 May 2011 20:13:05 +0000

Fuente:

RCT

Reliable Cancer Therapies (RCT) lanzará “Guías para Pacientes” en su sitio web. La creación de estas Guías es el resultado de una colaboración de RCT con la European Society for Medical Oncology (ESMO).
Las Guías para Pacientes son documentos que contienen información relevante detallada para sus enfermedades, escritas en una manera que puede ser facilmente comprendida. Esta información está basada en las Guías de Práctica Clínica de la ESMO, usada por los médicos como referencia del mejor estándar de cuidado.

Haga clic aquí para tener acceso a las Guías para pacientes.

RCT ha preparado las Guías para Pacientes en colaboración estrecha con la ESMO y su Cancer Patients Working Group (Grupo de Trabajo de Pacientes). RCT espera lograr su meta de expandir opciones de tratamiento basadas en evidencia para pacientes.

La Dra. Martine Piccart, Directora del Departamento de Medicina en el Instituto Jules Bordet en Bruselas, Bélgica, Presidenta electa de ESMO y miembro del Consejo Consultivo de RCT, indica: “Veo la iniciativa de las Guías para Pacientes por RCT y ESMO de mucho valor, no como un substituto para la interacción personal, pero sí como una nueva herramienta para una comunicación clara a pacientes acerca de su enfermedad, su tratamiento y seguimiento.”

Las Guías para Pacientes también están disponibles en el sitio web de la ESMO como parte de un nuevo servicio en línea, el cual provee a los pacientes un amplio rango de fuentes de referencia.

Leer el artículo completo aquí.

el artículo completo

La función del nervio vago en el pronóstico del cáncer

Ann-Christine Moenaert — Mon, 09 May 2011 15:12:39 +0000

Fuente:

RCT

El 28 de abril 2011, RCT firmó un contrato con el Profesor Yori Gildron, psicólogo de la Vrije Universiteit Brussel (Universidad Libre de Bruselas), y con su rector, el Profesor De Knop. RCT apoyará al Profesor Gidron y su equipo en su investigación sobre el nervio vago y su importancia en el cáncer.

Esta investigación, que se compone de cuatro estudios, indicará la posible función de la estimulación del nervio vago en el pronóstico y tratamiento del cáncer.

Puede obtener más información sobre este proyecto aquí.

RCT presente en el lanzamiento de M-icab, una iniciativa de la Coalición Europea de Pacientes de Cáncer

Ann-Christine Moenaert — Wed, 20 Apr 2011 13:11:24 +0000

Fuente:

RCT

El martes, 22 de marzo, el lanzamiento del comité consultivo independiente sobre el melanoma (M-icab) marcó un momento histórico en la lucha contra el cáncer. Gauthier Bouche, de RCT, estuvo presente en la ceremonia de lanzamiento de este comité consultivo.

La Coalición Europea de Pacientes de Cáncer ha decidido lanzar una serie de comités consultivos independientes sobre el cáncer, paneles asesores liderados por pacientes, que tienen como misión identificar las soluciones innovadoras contra el cáncer, especialmente para los tipos de neoplasias raras y poco estudiadas.

La misión de M-icab comprende cuatro aspectos, a saber:

Ofrecer a los pacientes afectados por el melanoma una identidad comunitaria mediante la creación de cohesión y la posibilidad de participar en la toma de decisiones relativas a su enfermedad.
Ofrecer a la industria, investigadores y personal médico una manera única de relacionarse entre ellos y de comunicarse con los pacientes con melanoma.
Comunicar a los pacientes las iniciativas tomadas por la industria, los investigadores y los médicos que trabajan en el campo del melanoma.
Desarrollar relaciones entre las asociaciones de pacientes con melanoma, tanto dentro como fuera del continente europeo.

Para obtener más información sobre el comité consultivo, visite www.m-icab.org.

Nuevas terapias en el sito web: aromaterapia, extracto de germen de trigo fermentado, reflexología

Ann-Christine Moenaert — Thu, 07 Apr 2011 09:56:03 +0000

Fuente:

RCT

Los nuevos resúmenes de CAM-Cancer sobre aromaterapia, sobre extracto de germen de trigo fermentado y sobre reflexología están disponibles en el sitio web.

Aromaterapia

Entre las afirmaciones terapéuticas de la aromaterapia en relación con pacientes con cáncer figuran la reducción de la tensión emocional, la tensión muscular, el dolor y la fatiga. Un estudio reciente que ha evaluado los posibles beneficios de la aromaterapia halló mejoras a corto plazo (hasta 8 semanas) en el bienestar psicológico, además de una reducción de la ansiedad y de la depresión, aunque el estudio no confirmó efectos a largo plazo.

La información para profesionales ha sido redactada por Katja Boehm y Thomas Osterman y revisada por el consorcio CAM-Cancer. La información para pacientes está basada en este informe y puede leerse aquí.

Extracto de Germen de Trigo

Se cree que la administración por vía oral del extracto de germen de trigo fermentado puede aumentar la eficacia de la quimioterapia y de la radioterapia, reducir sus efectos adversos y mejorar la calidad de vida de los pacientes. Si bien es verdad que los ensayos clínicos han obtenido por lo general resultados positivos, no existen por el momento pruebas concluyentes que respalden su uso como terapia contra el cáncer, dadas las fallas y limitaciones de dichos estudios.

La información para profesionales ha sido redactada por Alexander Kalisch y Markus Honeber y revisada por el consorcio CAM-Cancer. La información para pacientes está basada en este informe y puede leerse aquí.

Reflexología

Las investigaciones apuntan a que no pueden extraerse conclusiones definitivas sobre la eficacia de este tratamiento debido a las limitaciones metodológicas. Aunque la reflexología tiene un buen historial de seguridad, preocupa el hecho de que algunos reflexólogos intenten diagnosticar enfermedades como parte de su paquete de tratamiento con unas competencias insuficientes.

La información para profesionales ha sido redactada Helen Cooke y revisada por el consorcio CAM-Cancer. La información para pacientes está basada en este informe y puede leerse aquí.

La compañía belga Galápagos lanza un ensayo clínico de fase 1b

Ann-Christine Moenaert — Thu, 17 Mar 2011 15:40:26 +0000

Fuente:

RCT

El 14 de marzo de 2011, la compañía belga Galápagos NV anunció que había lanzado un ensayo clínico de fase 1b para GLPG0187, un nuevo medicamento en proceso de elaboración para el cáncer metastásico. El cáncer metastásico es responsable de la mayor parte de las muertes relacionadas con el cáncer en los Estados Unidos.

En este ensayo clínico, Galápagos quiere evaluar la seguridad y la eficacia preliminar de GLPG0187 en pacientes con cáncer.

GLPG0187, un antagonista de receptores de integrina, ya se había estudiado en animales: se comprobó que la administración por vía oral de este nuevo medicamento inhibía numerosos procesos relacionados con la propagación y crecimiento de tumores metastásicos. Después de la fase 1a del estudio en voluntarios saludables, la fase 1b se está realizando en pacientes con tumores sólidos. Los candidatos para participar en este ensayo son pacientes con un diagnóstico confirmado de cáncer avanzado, recurrente o metastático, para los que no existen terapias convencionales o que son refractarios a los tratamientos habituales.

Galápagos es una compañía belga de biotecnología, especializada en el descubrimiento y desarrollo de terapias de moléculas pequeñas y de anticuerpos con innovadores modos de acción.

Para más información, puede enviar un correo electrónico a ir@glpg [dot] com.
Para una información detallada acerca del ensayo clínico, haga clic aquí.

RCT participa en el congreso de Annie Appleseed Project

Ann-Christine Moenaert — Tue, 15 Mar 2011 13:28:28 +0000

Fuente:

RCT

En marzo de 2011, Annie Appleseed Project celebró un congreso en West Palm Beach, Florida (Estados Unidos). Annie Appleseed Project es una organización sin fines de lucro formada en su totalidad por voluntarios que ofrecen apoyo e información sobre tratamientos complementarios y alternativos a pacientes de cáncer y a supervivientes de la enfermedad.

Dado que el tema de esta conferencia –terapias complementarias y alternativas basadas en evidencias– es de gran interés para RCT, nuestra organización recibió una invitación para presentar nuestro trabajo. Klara Rombauts, una de las científicas que trabaja para RCT, dio una conferencia el pasado sábado 5 de marzo. Su conferencia, sobre la eficacia de los tratamientos convencionales y no convencionales, despertó un gran interés tanto entre pacientes y supervivientes de la enfermedad, como entre los profesionales médicos presentes.

Para un gran número de pacientes resultó alentador saber que RCT está dispuesto a financiar proyectos que no reciben fondos de la industria farmacéutica debido a un margen de ganancias potencialmente reducido.

Puede consultar las opiniones y comentarios sobre la conferencia en el siguiente enlace: http://www.tamiboehmer.com/2011/03/chew-your-food-and-other-appleseed-conference-takeaways/

Nuevas terapias en el sitio web: dosis elevadas de vitamina C por vía intravenosa y homeopatía

Ann-Christine Moenaert — Mon, 07 Mar 2011 09:55:44 +0000

Fuente:

RCT

Los nuevos resúmenes de CAM-Cancer sobre la administración de dosis elevadas de vitamina C por vía intravenosa y sobre homeopatía están disponibles en el sitio web.

Existen pocas pruebas que confirmen que una dosis elevada de vitamina C por vía intravenosa mejore la calidad de vida de los pacientes con cáncer avanzado. Aunque el procedimiento es seguro y provoca solo algunos efectos adversos leves, también podría reducir los efectos terapéuticos de las terapias convencionales contra el cáncer.

La información para profesionales ha sido redactada por Luc Geeraert y revisada por el consorcio CAM-Cancer. La información para pacientes está basada en ese informe y puede leerse aquí.

La homeopatía es un sistema de medicina basado en el principio de semejanza (“lo semejante se cura con lo semejante”). No existen riesgos graves asociados a la homeopatía, pero sí riesgos indirectos si los preparados homeopáticos se utilizan como reemplazo de los tratamientos convencionales del cáncer. En general, el balance riesgo-beneficio de esta terapia es positivo.

La información para profesionales ha sido redactada por Edzard Ernst y revisada por el consorcio CAM-Cancer. La información para pacientes está basada en este informe y puede leerse aquí.

Nuevas terapias en el sitio web: melatonina y selenio

Ann-Christine Moenaert — Tue, 01 Mar 2011 13:40:20 +0000

Fuente:

RCT

Los nuevos resúmenes de CAM-Cancer sobre la melatonina y el selenio están disponibles en el sitio web.

La melatonina se produce de forma natural en el cuerpo. Las pruebas de los ensayos clínicos sugieren que la melatonina podría influir positivamente en la remisión tumoral y el tiempo de supervivencia, e incluso podría proteger de los efectos adversos de los tratamientos contra el cáncer. Los suplementos de melatonina suelen considerarse seguros, al menos en una administración a corto plazo.

La información para profesionales sobre la melatonina ha sido redactada por Markus Horneber y revisada por el consorcio CAM-Cancer. La información para pacientes está basada en este informe y puede leerse aquí.

El papel del selenio como tratamiento del cáncer y como tratamiento y prevención de los efectos adversos derivados de las terapias no es claro. Aunque el selenio es un oligoelemento fundamental, también es tóxico en dosis altas y puede causar efectos adversos cuando se administran dosis elevadas durante un largo periodo de tiempo.

La información para profesionales sobre el selenio ha sido redactada por Gabrielle Dennert y revisada por el consorcio CAM-Cancer. La información para pacientes está basada en este informe y puede leerse aquí.

Curso de mindfulness (atención plena) para pacientes con cáncer y sus allegados

Ann-Christine Moenaert — Tue, 22 Feb 2011 14:34:51 +0000

Fuente:

RCT

Al diagnosticar un cáncer, las personas afectadas suelen experimentar tensión y emociones intensas. Ese estrés emocional puede afectar de forma negativa al proceso de recuperación y a la calidad de vida de los pacientes de cáncer.

El Hospital universitario de Bruselas lleva a cabo actualmente el ensayo clínico “Mindfulness Based Stress Reduction: Supportive Treatment for Adult Patients with Cancer and Their Partners” (Reducción del estrés basada en mindfulness (atención plena): tratamiento de apoyo para pacientes adultos con cáncer y sus allegados), con personas que se enfrentan al cáncer, ya sea como paciente o como allegado. Este ensayo requiere que los participantes se comprometan durante una hora al día a practicar ciertas técnicas en casa con la ayuda de un CD de audio y un libro de ejercicios. La parte del ensayo clínico que se realiza en el Hospital universitario de Bruselas tiene lugar en días laborables y dura unas dos horas.

Ineke Van Mulders, psicóloga clínica del Hospital universitario de Bruselas, es la directora de este ensayo. Ha recibido una formación especializada en el Instituut voor mindfulness (Instituto de mindfulness) de Países Bajos.

El mindfulness o terapia de atención plena consiste en tratar de forma consciente, con una mente abierta, las experiencias propias. En estos cursos se desarrolla la capacidad para abordar las experiencias de forma clara y moderada, ya sean placenteras o dolorosas y difíciles.

Para más información sobre este ensayo clínico, puede consultar:
http://www.clinicaltrial.gov/ct2/show/NCT01074528?term=NCT01074528&rank=1 (en inglés)
Si desea obtener información más concreta sobre mindfulness, puede enviar un correo electrónico a: ineke [dot] vanmulders@uzbrussel [dot] be o www.uzbrussel.be.

La primera conferencia Integrative Cancer Care for the Future

Ann-Christine Moenaert — Thu, 10 Feb 2011 15:28:34 +0000

Fuente:

RCT

RCT patrocina la primera conferencia Integrative Cancer Care for the Future (en español: cuidados integrales para el cáncer para el futuro). El presidente de la Conferencia es Barrie R. Cassileth, máster en ciencias y PhD. Barrie R. Cassileth también es presidente de Laurance S. Rockefeller en los cuidados integrales y líder del Centro Sloan-Kettering, investigacion contra el cáncer. La conferencia tendría lugar en Arnhem, Países Bajos, el 11 y 12 de marzo 2011. La conferencia está pensada para los profesionales de Oncología y de otros campos relacionados.

En el primer día, una mesa redonda se celebrará en la tarde (sólo con invitación). Los líderes de la política sanitaria discutirán sobre asuntos reglamentarios, la educación, los aspectos económicos y políticos y los retos para el futuro. En el segundo día, que está abierta al público, habrá presentaciones sobre cómo la oncología integral está organizada en diferentes partes del mundo por los líderes internacionales en la materia, tales como el Prof. George Lewith de la Universidad de Southampton de la escuela medicina.

Integrative Care for the Future es una organización internacional dedicada al apoyo, la investigación y la difusión de terapias complementarias basadas en evidencias que se utilizan para controlar los síntomas asociados con el cáncer y otras enfermedades graves.

Más información: http://www.integrativecareftfuture.org/

Profesor Volker Diehl, miembro del consejo consultivo de RCT, recibió un prestigioso premio

Ann-Christine Moenaert — Mon, 03 Jan 2011 14:07:41 +0000

Fuente:

RCT

El 20 de diciembre de 2010, el Dr. Volker Diehl, MD, PhD, miembro del consejo consultivo de RCT y pionero en el campo del linfoma de Hodgkin recibió el premio Wallace H. Coulter por logros de toda una vida en Hematología, de la Sociedad Americana de Hematología (American Society of Hematology ). Este premio se otorga a una persona que ha demostrado un compromiso de por vida y una gran contribución en el campo de la hematología; y a quién ha hecho un impacto importante en la educación, la investigación, o la práctica de la profesión.

Los logros científicos del Dr. Diehl incluyen el descubrimiento del rol del virus de Epstein-Barr en la mononucleosis infecciosa y su relación con el linfoma de Hodgkin. El también realizó el primer cultivo de líneas celulares de Hodgkin y lideró el desarrollo del régimen de quimioterapia BEACOPP (Bleomicina, Etopósido, Adriamicina, Ciclofosfamida, Oncovin, Procarbazina, Prednisona) para el tratamiento del linfoma de Hodgkin.

Al recibir el premio, el Dr. Diehl atribuyó sus logros a su obstinación de no renunciar a pesar de los 427 fracasos en intentar cultivar las líneas celulares de Hodgkin in vitro. También le dijo al público que ver pacientes jóvenes luchando contra el linfoma de Hodgkin le hizo decidirse a luchar contra esta enfermedad. Según el Dr. Diehl estos pacientes son los verdaderos héroes de la ciencia.

Ensayo clínico de dicloroacetato (DCA)

Ann-Christine Moenaert — Sun, 05 Dec 2010 20:21:42 +0000

Fuente:

RCT

El DCA es un compuesto químico que no se produce de forma natural en el cuerpo ni en la naturaleza. Se considera un elemento potencialmente peligroso, incluso un posible carcinógeno, pero en la actualidad está probándose para el tratamiento contra el cáncer.
Para obtener más información, haga clic aquí.

Algunas pruebas indican que el DCA puede funcionar como tratamiento del glioblastoma multiforme, un tipo de cáncer cerebral. Un estudio reciente ha señalado que el DCA puede provocar la muerte de las células de glioblastoma multiforme. La dosis administrada a los pacientes con glioblastoma no pareció ser tóxica para los sistemas renal, cardíaco, hepático y hematológico. Sin embargo, puesto que este experimento únicamente incluyó cinco pacientes, no permite llegar a conclusiones definitivas. La Universidad de Alberta (Canadá) está realizando ensayos clínicos para continuar la investigación sobre el efecto del DCA.
Más información: http://www.ncbi.nlm.nih.gov/pubmed/20463368

Además, RCT financia actualmente un ensayo en pacientes con tumores cerebrales malignos recurrentes que está realizándose en la Universidad de Florida, donde lleva investigándose el uso clínico del DCA durante décadas.
Este ensayo ahora está abierto para la participación de pacientes. No hay limitaciones en cuanto al número de recurrencias ni tipos de tratamientos anteriores. Los responsables de este ensayo son el Dr. Erin Dunbar y el Dr. Peter Stacpoole.
Más información: http://clinicaltrials.gov/ct2/show/NCT01111097?term=DCA&recr=Open&state1=NA%3AUS%3AFL&rank=1

Reliable Cancer Therapies lanza un sitio web a nivel mundial sobre terapias para el cáncer

Ann-Christine Moenaert — Tue, 30 Nov 2010 13:37:58 +0000

Fuente:

RCT

Comunicado de prensa

Strombeek-Bever, Bélgica, 30 de noviembre de 2010 – Reliable Cancer Therapies (RCT) es una organización suiza sin fines de lucro que proporciona información basada en la investigación sobre terapias para el cáncer y financia de manera selectiva el desarrollo de terapias prometedoras.
Reliable Cancer Therapies lanzó hoy una base de datos en línea a nivel mundial (www.reliablecancertherapies.com) que proporciona información científicamente verificada sobre tratamientos contra el cáncer. Con esta base de datos en línea, RCT espera ampliar las opciones de tratamiento seguras para los pacientes con cáncer.

"Nuestra base de datos en línea proporciona a los pacientes y a los profesionales médicos información gratuita y cualitativa sobre tratamientos para el cáncer, directrices y ensayos clínicos”, indica la Dra. Lydie Meheus, directora ejecutiva de RCT. La Dra. Meheus también agregó: "Este sitio web es una respuesta a la creciente necesidad de una completa base de información segura y fidedigna sobre tratamientos para el cáncer y medicamentos en fase de investigación. Damos información específica y verificada sobre terapias convencionales para el cáncer así como no convencionales, y queremos centrarnos en los resultados obtenidos por los pacientes. Esperamos que esta base de datos ayude a que las personas se orienten en torno a una información abrumadora, confusa y con mucha frecuencia sin verificar. Sin embargo, hay que hacer hincapié en que RCT no proporciona consejo médico y nuestro sitio web no sustituye a una consulta médica".

Permitir elecciones equilibradas
El equipo de RCT tiene la convicción de que proporcionar acceso a la información verificada cubre el vacío existente entre la asistencia sanitaria convencional y la no convencional y facilita su integración. La Información de RCT citada en el sitio web ha sido investigada para comprobar su evidencia, permitiendo hacer así elecciones de tratamientos basados en la evidencia.

Para pacientes y profesionales sanitarios
El sitio web de RCT proporciona información basada en la investigación en diferentes redacciones para pacientes y sus familiares y para profesionales para que pueda ser utilizada para hablar sobre las opciones de tratamiento. La información no profesional está disponible en inglés, francés, español y holandés. El sitio web está creciendo constantemente y se actualiza de manera regular. La navegación y la búsqueda permiten un acceso directo al tema solicitado.

Consejo consultivo
El equipo de RCT es independiente e imparcial. Organizaciones internacionales (ESMO, CAM-CANCER,…) colaboran con el desafiante esfuerzo de conseguir los mejores datos verificados disponibles para la base de datos en línea. RCT cuenta con el apoyo de un consejo consultivo de alto nivel, compuesto por miembros de reconocido prestigio:
o Prof. Bert Aertgeerts, Bélgica
o Prof. Marc Bracke, Bélgica
o Prof. Volker Diehl, Alemania
o Prof. Moshe Frenkel, Israel
o Prof. Robert Gatenby, EE. UU.
o Prof. Martine Piccart, Bélgica
o Prof. Eric Van Cutsem, Bélgica

RCT también busca constantemente terapias para el cáncer que, basadas en resultados medibles, parecen exitosas, pero que nunca han sido investigadas de manera rigurosa. Si en el transcurso de estas investigaciones se identifican nuevos y prometedores tratamientos para el cáncer que carecen del respaldo de la industria o de organizaciones institucionales, podrá financiarse el desarrollo adecuado de tales terapias. Información sobre los proyectos actualmente financiados por RCT está disponible en la página web de RCT.

Petición de ayuda
Los pacientes o médicos que quieran contribuir a la creación de este centro de conocimiento en línea, todavía pueden hacerlo proporcionando detalles sobre su tratamiento contra el cáncer y el resultado utilizando el Formulario de Registro de Casos en el sitio web de RCT.

Cooperación entre CAM-Cancer y Reliable Cancer Therapies

RCT Editor — Thu, 04 Nov 2010 09:30:40 +0000

Fuente:

RCT

El 5 de mayo de 2010 se estableció un acuerdo histórico para fomentar la financiación y la cooperación entre Reliable Cancer Therapies (RCT) y el National Research Center in CAM (NAFKAM) en Noruega. NAFKAM gestiona la página web de CAM-cancer www.cam-cancer.org en colaboración con el National Information Center for CAM (NIFAB), ambos con sede en la Universidad de Tromsø.

Los dos proyectos sin fines de lucro, CAM-Cancer y RCT, ofrecen información científicamente comprobada sobre tratamientos contra el cáncer basados en pruebas y trabajaran en estrecha colaboración. RCT se comprometió amablemente a apoyar financieramente el proyecto CAM-cancer hasta finales de 2011.

El proyecto CAM-Cancer es dirigido por el profesor Vinjar Fønnebø mientras que RCT es dirigido por la Dra. Lydie Meheus, la directora ejecutiva de RCT.